Pfizer's point-of-view
Executive Summary
"You realize of course that wholesalers play games with us here, wanting to take more inventory in advance of price increases and then kind of hiding that from us for the next few months," Pfizer President Henry McKinnell, PhD, explained to investors. "We think that at this point, five or six months after our price increase, that sort of nonsense has smoothed out...Inventory should be in balance." The timing of the trade stocking patterns allowed Pfizer to post an unusually strong quarter for the January-March period while closing out the hostile takeover of Warner-Lambert
You may also be interested in...
Wholesaler Forward-Buying Is Back, J&J Says; Rx Price Increases Pick Up
Johnson & Johnson is seeing an upward trend in forward-buying by wholesalers, CFO Robert Darretta told analysts Jan. 23 in New York City.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011